Antibodies - Primary Antibodies - CD44 Splice Variants - Cosmo Bio USA
Close

Site Information

CD44v

 

 

NameHostAntigen SpeciesX-reactCloneAppplicationsSize
Anti CD44 v10-e16 [ Cat No. CAC-LKG-M002 ] RT MS MS RM1 FC 100UG
Anti CD44 v9 [ Cat No. CAC-LKG-M001 ] RT HU HU RV3 WB IHC(p) IF ELISA FC IP 100UG
Anti CD44ICD [ Cat No. KAL-KO601 ] RAB HU HU   WB IHC IC IF IP 200UG

 

 

Year Publications citing anti-CD44 splice variant clone RM1 or RV3 click for PubMed Entry
2017

Nishino, M., Ozaki, M., Hegab, A. E., Hamamoto, J., Kagawa, S., Arai, D., ... & Betsuyaku, T. (2017). Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. Journal of Cancer, 8(10), 1774-1785.

Anti-human CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was used in immunohistochemistry and flow cytometry to screen multiple lung cancer cell lines for properties associated with cancer stem cells (CSCs). Staining for aldehyde dehydrogenase (ALDH) was also combined with CD44v9 with the hope of improving the ability to detect CSCs. The results suggest that CD44v9 is a good marker for lung CSCs in human lung adenocarcinoma cell lines. Use of ALDH as second marker provided evidence that lung CSCs may be heterogeneous with different CSC properties distributed over distinct cell subsets.
PMID: 28819374
2017

Choi, E. S., Kim, H., Kim, H. P., Choi, Y., & Goh, S. H. (2017). CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer. Scientific Reports, 7.

Anti-human CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was used to demonstrate predominant expression of CD44v8-10 in gastric cancer cell lines and advanced gastric tumors. CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was conjugated with near infrared red (NIR) fluors ATTO680 for immunohistochemical detection of CD44v8-10-expressing cells in gastric tumor tissues; and Methylene Blue (MB) for use in in vitro photoimmunotherapy. MB causes not only NIR fluorescence, but also the highly efficient generation of singlet oxygen, thereby selectively killing cancer cells. In mixtures of cell lines either expressing CD44v8-10 or not and stained with MB-conjugated CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) only the CD44v8-10-expressors were subject to photolysis. Together, the results suggest the applicability of CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) for NIR fluorescence detection and photoimmunotherapy of both primary gastric cancer cells and disseminated cancer stem cell-like CD44v8-10(+) cells in the peritoneal cavity in advanced gastric cancer.
PMID: 28694503
2017

Miwa, T., Nagata, T., Kojima, H., Sekine, S., & Okumura, T. (2017). Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer. International Journal of Oncology.

Anti-human CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was used in flow cytometry to sort and analyze the human gall bladder cancer cell line NOZ. The NOZ cell line is shown to comprise two populations that express different CD44 isoforms: CD44s and CD44v9, accounting for 70% and 30% of the CD44+ cells, respectively. Interestingly, the CD44s cells exhibited elevated migration and invasion phenotypes and expressed mesenchymal markers ZEB1, ZEB2 and Vimentin while the CD44v9 cells did not. Instead, they exhibited enhanced tumorigenicity in a mouse xenograft model and expressed high levels of the epithelial marker E-cadherin and the splicing factor ESRP1. Also, subculture of CD44v9 cells gave rise to both CD44v9 and CD44s cells, while subculture of CD44s cells only gave rise to CD44s cells.
PMID: 28677740
2017

Mvunta, D. H., Miyamoto, T., Asaka, R., Yamada, Y., Ando, H., Higuchi, S., ... & Shiozawa, T. (2017). SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells. Translational Oncology, 10(4), 621-631.

Anti-human CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was used in immunoblot assays to show that SIRT1 upregulates CD44v9 in ovarian carcinoma cells, correlating with acquisition of enhanced resistance to oxidative stress. Genetic and pharmacological knockdown of SIRT1 downregulated CD44v9 while upregulation led to enhanced CD44v9. The cancer stem cell marker CD44v9 is known to be involved in stabilizing the xCT glutamate-cystine antiporter system that promotes GSH production and protection from ROS.
PMID: 28667895
2017

Otsubo, K., Nosaki, K., Imamura, C. K., Ogata, H., Fujita, A., Sakata, S., ... & Seto, T. (2017). Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non–small cell lung cancer. Cancer Science. ELISA?

Anti-human CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was used to show that effectiveness of salazosulfapyridine treatment in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer was associated with an increase in serum CD44v9, likely due to apoptotic death of CD44v9+ CSC. Serum samples collected from 14 patients before and after 21 days of salazosulfapyridine treatment were tested by ELISA for human CD44v9 (from Cosmo Bio). The amount of free CD44v in serum was calculated relative to the absorbance of 1 uL culture supernatant of the CD44v9-positive cell line OSC 19 as 1 unit.
PMID: 28667792
2017 Miyano, K., Cabral, H., Miura, Y., Matsumoto, Y., Mochida, Y., Kinoh, H., ... & Kataoka, K. (2017). cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells. Journal of Controlled Release, 261, 275-286. PMID: 28666729
2017

Kasai, S., Furuichi, Y., Ando, N., Kagami, K., Abe, M., Nakane, T., ... & Okazaki, S. (2017). Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression. Cell Death & Disease, 8(6), e2857.

Ultra low molecular weight hyaluronan is shown to induce features consistent with necrotic cell death in B-precursor leukemia cells that express high levels of CD44. Anti-human CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was used in flow cytometry to show that this property did not correlate with the magnitude of ultra-low molecular weight hyaluronan-mediated inhibition of leukemic cells.
PMID: 28569787
2017 Jeong, S., Choi, E., Petersen, C. P., Roland, J. T., Federico, A., Ippolito, R., ... & Romano, M. (2017). Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis. United European gastroenterology journal, 5(1), 37-44. PMID: 28405320
2017 Yamakawa, Y., Kusuhara, M., Terashima, M., Kinugasa, Y., Sugino, T., Abe, M., ... & Yamaguchi, K. (2017). CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues. Biomedical Research, 38(1), 41-52. PMID: 28239031
2017 Petersen, C. P., Meyer, A. R., De Salvo, C., Choi, E., Schlegel, C., Petersen, A., ... & Pizarro, T. T. (2017). A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut, gutjnl-2016. PMID: 28196875
2017 Burclaff, J., Osaki, L. H., Liu, D., Goldenring, J. R., & Mills, J. C. (2017). Targeted apoptosis of parietal cells is insufficient to induce metaplasia in stomach. Gastroenterology, 152(4), 762-766. PMID: 27932312
2016 Hiraga, T., & Nakamura, H. (2016). Comparable roles of CD44v8-10 and CD44s in the development of bone metastases in a mouse model. Oncology letters, 12(4), 2962-2969. PMID: 27698884
2016 Kobayashi, K., Matsumoto, H., Matsuyama, H., Fujii, N., Inoue, R., Yamamoto, Y., & Nagao, K. (2016). Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Oncology reports, 36(5), 2852-2860. NEEDS CONFIRMATION PMID: 27599396
2016 Matsukuma, S., Yoshimura, K., Ueno, T., Oga, A., Inoue, M., Watanabe, Y., ... & Eguchi, H. (2016). Calreticulin is highly expressed in pancreatic cancer stem-like cells. Cancer science, 107(11), 1599-1609. PMID: 27561105
2016 Sosulski, A., Horn, H., Zhang, L., Coletti, C., Vathipadiekal, V., Castro, C. M., ... & Donahoe, P. K. (2016). CD44 splice variant v8-10 as a marker of serous ovarian cancer prognosis. PloS one, 11(6), e0156595. PMID: 27253518
2016 Thanee, M., Loilome, W., Techasen, A., Sugihara, E., Okazaki, S., Abe, S., ... & Titapun, A. (2016). CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment. Cancer science, 107(7), 991-1000. MOUSE PMID: 27176078
2016 Hagiwara, M., Kikuchi, E., Kosaka, T., Mikami, S., Saya, H., & Oya, M. (2016, August). Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality. In Urologic Oncology: Seminars and Original Investigations (Vol. 34, No. 8, pp. 337-e19). Elsevier. PMID: 27133224
2016 Wang, M., Miura, Y., Tsuchihashi, K., Miyano, K., Nagano, O., Yoshikawa, M., ... & Saya, H. (2016). Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines. Journal of Controlled Release, 230, 26-33. PMID: 27040816
2016 Kakehashi, A., Ishii, N., Sugihara, E., Gi, M., Saya, H., & Wanibuchi, H. (2016). CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma. Cancer science, 107(5), 609-618.  PMID: 26882440
2016 Yamada, Y., Miyamoto, T., Kashima, H., Kobara, H., Asaka, R., Ando, H., ... & Shiozawa, T. (2016). Lipocalin 2 attenuates iron-related oxidative stress and prolongs the survival of ovarian clear cell carcinoma cells by up-regulating the CD44 variant. Free radical research, 50(4), 414-425. PMID: 26729415
2016 Choi, E., Hendley, A. M., Bailey, J. M., Leach, S. D., & Goldenring, J. R. (2016). Expression of activated Ras in gastric chief cells of mice leads to the full spectrum of metaplastic lineage transitions. Gastroenterology, 150(4), 918-930. NEEDS CONFIRMATION PMID: 26677984
2015 Maruyama, Y., Uehara, T., Daikuhara, S., Kobayashi, Y., Nakajima, T., Matsumoto, A., ... & Ota, H. (2015). Clinicopathological characterisation of duodenal adenocarcinoma with high CD44 variant 9 expression. Pathology, 47(7), 647-652. PMID: 26517627
2015 Umeda, T., Ishida, M., Murata, S., Mori, T., Kawai, Y., Itoi, N., ... & Kubota, Y. (2016). Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer, 23(6), 869-875. PMID: 26494575
2015 Aso, T., Matsuo, M., Kiyohara, H., Taguchi, K., Rikimaru, F., Shimokawa, M., ... & Masuda, M. (2015). Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer. PloS one, 10(3), e0116596. PMID: 25751671
2015 Kiuchi, S., Ikeshita, S., Miyatake, Y., & Kasahara, M. (2015). Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis. Experimental and molecular pathology, 98(1), 41-46. NEEDS CONFIRMATION PMID: 25481101
2015 Ishimoto, T., Izumi, D., Watanabe, M., Yoshida, N., Hidaka, K., Miyake, K., ... & Iwagami, S. (2015). Chronic inflammation with Helicobacter pylori. Journal of gastroenterology, 50(7), 751-757. PMID: 25479940
2014 Hashimoto, N., Tsunedomi, R., Yoshimura, K., Watanabe, Y., Hazama, S., & Oka, M. (2014). Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC cancer, 14(1), 722. PMID: 25260650
2012 Masuko, K., Okazaki, S., Satoh, M., Tanaka, G., Ikeda, T., Torii, R., ... & Ohno, Y. (2012). Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS One, 7(1), e29728. RV3 no Cosmo PMID: 22272243
2011 Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., ... & Masuko, T. (2011). CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth. Cancer cell, 19(3), 387-400. PMID: 21397861
    There are no products in this category.
‚Äč